Effects of FMO3 Polymorphisms on Pharmacokinetics of Sulindac in Chinese Healthy Male Volunteers

Table 3

Mean pharmacokinetic parameters of sulindac, sulindac sulfide, and sulindac sulfone for FMO3 HHDD () and FMO3 hhdd ().

	FMO3 HHDD	FMO3 hhdd
Sulindac
(ng·h·mL^−1)	27.93 ± 8.85	41.88 ± 17.37
(ng·h·mL^−1)	22.82 ± 7.87	35.16 ± 9.60
(ng·mL^−1)	6.95 ± 3.28	11.87 ± 4.80
(h)	1.82 ± 1.07	1.64 ± 0.48
(h)	4.01 ± 1.24	4.46 ± 1.30
Sulindac sulfide
(ng·h·mL^−1)	43.69 ± 15.23	49.67 ± 25.92
(ng·h·mL^−1)	32.93 ± 15.59	32.22 ± 13.56
(ng·mL^−1)	32.93 ± 15.59	32.22 ± 13.56
(h)	2.43 ± 1.59	3.07 ± 1.17
(h)	10.18 ± 3.28	9.77 ± 3.97
Sulindac sulfone
(ng·h·mL^−1)	65.64 ± 16.98	65.69 ± 24.34
(ng·h·mL^−1)	48.18 ± 0.31	42.76 ± 14.67
(ng·mL^−1)	3.43 ± 1.19	3.69 ± 1.61
(h)	2.57 ± 0.98	2.86 ± 1.07
(h)	12.19 ± 2.44	10.62 ± 2.31

, maximum plasma concentration; AUC, area under plasma concentration-time curve; , time of maximum plasma concentration; , half-life of elimination. .